{"url_path":"/sec/cik-0000786947/8-k/2026-06-29/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/786947/0001104659-26-078839-index.html","accession_number":"0001104659-26-078839","cik":"0000786947","ticker":null,"issuer_name":"ACURA PHARMACEUTICALS, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/786947/0001104659-26-078839-index.html","primary_entity_key":"0000786947","primary_entity_name":"ACURA PHARMACEUTICALS, INC"},"word_count":299,"has_tables":true,"body_markdown":"false\n0000786947\n\n0000786947\n\n2026-06-29\n2026-06-29\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D. C. 20549**\n\n \n\n**FORM 8-K**\n\n** **\n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of the Securities\nExchange Act Of 1934**\n\n** **\n\nDate of Report (Date of earliest event reported):\n**June 29, 2026**\n\n \n\n \n\n** **\n\n**ACURA\nPHARMACEUTICALS, INC.**\n\n(Exact Name of Registrant as specified in its\nCharter)\n\n \n\n \n\n ** **\n\n**New York**\n**1-10113**\n**11-0853640**\n\n(State or other jurisdiction of\n\nincorporation or organization)\n(Commission File Number)\n(I.R.S. Employer\n\nIdentification Number)\n\n** **\n\n**616\nN. North Court****, Suite 120**\n\n**Palatine****,\nIllinois****60067**\n\n(Address of principal executive offices) (Zip\ncode)\n\n** **\n\n**(847****)\n705-7709**\n\n(Registrant’s telephone number, including\narea code)\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of Each Class**\n**Trading Symbol(s)**\n**Name of Each Exchange on Which Registered**\n\nCommon\nStock, $0.01 par value per share\nACUR\nOTC Market – OTC Expert Market\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨Written\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨Soliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n¨Pre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))\n\n \n\n¨Pre-commencement communications pursuant to Rule 13e-4(c) under\nthe Exchange Act (17CFR 240.13e-4(c))\n\n \n\nIndicate by check mark whether the registrant\nis an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the\nSecurities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\nGrowth Company ¨\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}